SCHEMBL4822110

SCHEMBL4822110

Clc1ccc(Oc2ccccc2C2=NCCN2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 7/20 0.52
LMNA P02545 1/20 0.50
RECQL P46063 1/20 0.50
PDCD1LG2 Q9BQ51 1/20 0.44
CD274 Q9NZQ7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9122502 0.85 NISCH (0.51) NISCHPDCD1LG2CD274
SCHEMBL4823981 0.82 NISCH (0.56) NISCHLMNA
SCHEMBL4815718 0.79 NISCH (0.54) NISCH
Pamoic Acid SCHEMBL9123814 0.78 GPR35 (0.50) NISCH
SCHEMBL8202723 0.77 NISCH (0.75) NISCHLMNARECQL
SCHEMBL4813698 0.77 NISCH (0.58) NISCH
SCHEMBL2949149 0.76 NISCH (0.62) NISCH
Formic Acid SCHEMBL4904523 0.76 NISCH (0.49) NISCHLMNA
SCHEMBL4815704 0.74 NISCH (0.70) NISCHLMNAPDCD1LG2CD274
SCHEMBL6747069 0.74 NISCH (0.47) NISCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0516234-B1 Phenoxyphenyl derivatives AKZO NOBEL NV (NL) 1995-09-13 EP claimed
US-5190965-A Treatment of depression AKZO N.V. (NL) 1993-03-02 US claimed
EP-0516234-A1 Phenoxyphenyl derivatives Akzo Nobel N.V. (NL) 1992-12-02 EP claimed
JP-5148197-A None JP disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
EP-0516234-B1 Phenoxyphenyl derivatives AKZO NOBEL NV (NL) 1995-09-13 EP disclosed
US-5430063-A Antidepressants AKZO N.V. (NL) 1995-07-04 US disclosed
JP-H05148197-A PHENOXYPHENYL DERIVATIVE AKZO NV 1993-06-15 JP disclosed
US-5190965-A Treatment of depression AKZO N.V. (NL) 1993-03-02 US disclosed
EP-0516234-A1 Phenoxyphenyl derivatives Akzo Nobel N.V. (NL) 1992-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof MC4R, MC5R, MC3R NISCH 1934/4885LMNA 2506/4885RECQL 3420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.